Structure and Function of the SHOC2 Holophosphatase Complex in RAS-driven Cancer
Structure and Function of the SHOC2 Holophosphatase Complex in RAS-driven Cancer
批准号:
10662750
负责人:
Jason Kwon
金额:
$14.72万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-05-01 至 2023-12-01
关键词:
AccelerationAmino Acid SubstitutionBindingBiological AssayBiologyBiophysicsCRISPR/Cas technologyCancer cell lineCell TherapyCell membraneClinicalComplexCycloheximideDataDevelopmentDrug resistanceEducational process of instructingEnzymesEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorFutureGenetic ScreeningGoalsHalf-LifeHomologous GeneImageImmunofluorescence ImmunologicImmunoprecipitationIn VitroKRAS2 geneKnowledgeLaboratoriesLeadLibrariesLysineMEKsMalignant NeoplasmsMalignant neoplasm of pancreasMapsMass Spectrum AnalysisMeasuresMediatingMitogen-Activated Protein Kinase InhibitorMitogen-Activated Protein KinasesModificationMuscleMutateMutationOncogenicOrganoidsOutcome StudyPathway interactionsPatientsPhasePositioning AttributePost-Translational Protein ProcessingProtein DephosphorylationProtein FamilyProtein InhibitionProteinsProteomicsRAF1 geneRAS driven cancerRecurrenceReporterReportingResearchResistanceScaffolding ProteinSignal TransductionSiteSpecificityStructural ModelsStructureSubstrate SpecificitySurfaceTherapeuticTrainingUbiquitinUbiquitinationVariantWorkcancer cellcrosslinkexperienceinhibitorinsightleukemialoss of functionmelanomamembermutantmutation screeningnovelnovel strategiesprogramsprotein functionprotein protein interactionprotein structure functionras Proteinsrational designrefractory cancerresistance mechanismresponsescaffoldsmall moleculestructural biologytargeted treatmenttherapeutic developmenttherapeutic targettumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract:
RAS proteins are found to be frequently mutated in clinical cases of cancer. Effective targeted therapies
against RAS and its downstream pathways have been highly sought after. Among the RAS effectors, the
RAF/mitogen-activated protein kinase (MAPK) cascade has been shown to be important for propagating
oncogenic signaling downstream of RAS. Many promising targeted therapies have been developed that
directly inhibit mutant KRAS and MAPK members but have been limited due to resistance mechanisms.
SHOC2 has been recently found to be a potent synthetic lethal vulnerability in various RAS mutant
contexts, including RAS-driven leukemia/melanoma and facilitates cancer resistance to numerous RAS/MAPK
inhibitors. SHOC2 is a scaffold that binds RAS and PP1C to form a ternary holophosphatase complex which
dephosphorylates inhibitory ‘S259’ on RAF proteins and enables MAPK signaling. To actualize SHOC2 as a
therapeutic target and inform future efforts to rationally design inhibitors against the complex, a deep
understanding of SHOC2 structural features that govern complex assembly and function is needed. We have
now resolved the SHOC2 complex structure and have profiled the functional consequence of nearly all
possible amino acid substitutions at every position of SHOC2 through deep mutational scanning.
These findings highlight novel structural features of SHOC2 that may be important to therapeutically target
in RAS mutant cancers. The studies outlined in this proposal will build on this work and aim to (1) define and
validate the structural features of SHOC2 holophosphatase complex specificity toward RAF substrate, and (2)
identify novel post-translational modifications that regulate SHOC2 function. The training I receive in the K99
phase will provide me the necessary expertise in structural biology, proteomics, and ubiquitin biology as well
as equip me with teaching/lab management experience so that I can effectively lead my own independent
research program. The K99/R00 will be instrumental in helping me achieve my long-term goal, to establish my
laboratory focused on studying novel RAS-associated vulnerabilities and drug resistance mechanisms via
systematic approaches in cell signaling and protein structure-function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the role of SHOC2 to enhance MEK inhibitor sensitivity in pancreatic cancer
-
批准号:10186717
-
项目类别:
-
资助金额:$6.64万
-
财政年份:2019
-
负责人:Jason Kwon
-
依托单位:
海外基金